Introduction
Revolutionary advances in research associated with the mapping of the human genome demonstrate the importance of genetics in human development and behavior and may deepen and widen belief in genetic determinism.
Indeed, to the cartoonist Scott Adams, creator of the syndicated 'Dilbert' strip, a person's genetic composition may determine even one's responses to the use of genetics in everyday life.
Public policy development, led by the disciplines of law and social sciences, is infinitely less precise than the development of biomedical sciences. Yet, public policy, too, appears driven in large measure by inexorable forces, sometimes referred to as 'trends,' 'priorities,' or, less frequently, 'imperatives. ' Several broad forces of public policy development will largely control, or determine, the near-term evolution of genetics policy in the United States and, perhaps, other Western or democratic countries. These forces include, inter alia, protection of individuals' medical privacy, costeffectiveness in public expenditures, and the power of anecdotal experience to diminish the power of data.
This paper outlines three arenas of genetic policy development: information, services and supply, and a model for addressing these issues. 
Information policies
Governments currently are struggling to craft laws, regulations and judicial rulings regarding many dimensions of access to information about an individual's genotype.
Controls on access to information
US legislators are sympathetic to people who fear losing employment opportunities or access to health insurance due to the use, or misuse, of genetic information. Exemplifying anti-discrimination legislation was a bill introduced before the US Congress in 1999 by Representative Louise Slaughter (D-NY). 1 The bill, the Genetic Non-discrimination in Health Insurance and Employment Act, would have prohibited federally regulated health insurance plans from discriminating against individuals on the basis of genetic information in enrollments, and would have prohibited employers from discriminating on the basis of predictive genetic information.
Although Congress failed to adopt the Slaughter bill, an executive order issued by former President Clinton does prohibit genetic discrimination in federal workplaces. 2 Besides the legislative and executive branches, the US judiciary is also addressing genetic discrimination issues. For example, the federal government brought an action, under the Americans with Disabilities Act, against a railroad company for requiring genetic testing for chromosome 17 deletion of employees who had filed claims for occupational injuries resulting from carpal tunnel syndrome. 3 Most states have adopted, or are considering, discrimination laws protecting asymptomatic individuals. One of the first to act was New Jersey. Legislation adopted by that state in 1996 prohibits the use of genetic information in health insurance enrollment and limits the use of gen-etic information in life insurance enrollment. 4 The Legislature did allow life insurers to prevent individuals who know they are likely to develop a fatal disease in the near future from obtaining life insurance at an advantageous rate.
There are many insurance implications of an individual's knowledge of his or her probability of contracting a disease. In a recent general population survey, more than two-thirds of respondents stated that they would purchase long-term care insurance were they to learn from a completely predictive genetics test that they would contract Alzheimer's disease. 5 With regard to confidentiality, Congress adopted a provision, as part of the Health Insurance Portability and Accountability Act (HIPAA) of 1996, prohibiting health insurers from using genetic information in making eligibility determinations. 6 However, to date the US Department of Health and Human Services' efforts to implement the HIPAA medical privacy and confidentiality provisions are confused and contentious.
The scope of privacy and confidentiality protections is not easily determined. Should insurers, in making eligibility or benefit determinations, be prevented from using information contained in a patient's family history, for example? The writer would suggest that insurance carriers should be prohibited from using family history against a patient in deciding whether to reimburse a requested health service. However, carriers should be permitted to use a family history to justify a genetic test.
Gene Therapy

Building databases
Recent activity in genomics is spurring interest in the development of databanks. Most famously, this activity includes the Human Genome Project, an international research program constructing genetic and physical maps of the human genome. 7 Celera is a private company that, among other activities, is generating, integrating, and analyzing biologic information to enable therapeutic discoveries. 8 Also, institutional members of the International Genome Sequencing Consortium contribute to the effort.
Building and manipulating databanks can produce clinically useful research results. Iceland, with a relatively homogeneous population of 275 000 and a comprehensive public health record system dating to 1915, has authorized deCode Genetics, Inc., to operate a complete genetic database in return for free access by citizens to diagnostic tests and drugs resulting from related research. 9 Another databank development effort -initiated by JD Watson, JH Clark, and others -was designed to recruit volunteers, through the Internet, to donate DNA to a 'gene trust' for medical research. 10 Researchers have also called for construction of a database on in utero exposure to chemicals, in order to prevent birth (or developmental) defects, and construction of databases to show which populations are at risk for obesity.
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Another scheme is to develop a secure, on-line databank, or 'gene pool', containing individuals' genetic profiles. 12 Sooner or later, these efforts can all expect to encounter well-intentioned demands for government oversight, which may impede administrative decisions. Officials tend to prefer that programs contract with only the lowest-cost suppliers and consultants, limit the numbers of individuals permitted to attend conferences, and avoid research avenues that are not easily justified to politicians.
Judicial evidence
In the law enforcement arena, genetic test results have helped convict or exonerate defendants and even exculpate prisoners previously convicted. President Clinton's impeachment in 1998 turned in part on the detection of genetic material on a dress worn by Monica Lewinsky, the young White House intern. Civil, or non-criminal, law cases also involve questions of the propriety of using genetic information in court. A judge perhaps would admit into evidence the results of a genetic test to determine paternity. Divorce courts may use genetic test results in resolving issues of child custody, by limiting, for example, the parental rights of a parent at risk of contracting Alzheimer's disease.
Policies controlling genetic services
The public will demand access to genetic testing and counseling with increasing fervor, raising issues about clinical standards and molecular diagnostics, the mandating of insurance benefits, resource allocation, and screening of populations at risk.
Standards of care
Clinical standards for genetic counseling and testing and recording of a family history, by primary care practitioners, are beginning to emerge despite inadequate physician training in genetics. 13 Routine physical examinations of adolescents and young adults may include genetic testing to help determine disease prevention strategies. Genetic testing requires the patient's informed consent -and in some cases, parental consent -which, in turn, requires knowledge of the implications of the test, including the likelihood of identifying the probability of disease in other family members.
The American Medical Association's Institute for Ethics has suggested that physicians recommend genetic testing only when test results will alter the family or patient's actions. 14 The Institute has further suggested that physicians inform the patient of the possibility of discrimination and of the physician's duty to inform the patient of test results that indicate the presence or risk of a disease that can be treated, managed or prevented. The Institute has advised genetic testing of children and embryos only for diseases that manifest in childhood. The Institute has not addressed the population-based health issue of whether to initiate random screening. For physicians who fail to follow dominant clinical standards, malpractice liability may result.
Harvard University's Risk Management Foundation recommends updating the family history periodically, discussing the implications of genetic tests with patients, and documenting treatment plans and patient concerns. 15 The foundation additionally recommends referrals to genetic counselors when appropriate, documenting responsibilities among different members of the health care team, and an effective system for collecting and reviewing test results. They say test results, follow-up actions, and lack of patient compliance should also be documented.
Some authorities advocate public oversight of genetic testing. The Advisory Committee on Genetic Testing supports Food and Drug Administration review of all genetic tests, already numbering in the hundreds, especially tests of currently untreatable diseases. The committee views Institutional Review Board review of tests in the research stage as critical. 16 The advisory committee was convened by the Secretary of the US Department of Health and Human Services, which also convened a Genetic Testing Work Group to address issues of proficiency testing of genetic tests and additional topics. 17 
Payments
To the extent that genetic testing and counseling are required under clinical standards of care, will insurance plans be required to pay for them? To date, reimbursement is inconsistent, and it is likely to remain so. Insurers will further resist paying for genetic counseling, which often is very time-consuming, and for gene therapy.
In the United States, patients and family members often advocate for reimbursement for services individually. This leads both to exceptions benefiting especially assertive individuals and to the expansion of benefits based on emotionally appealing anecdotes. An ad hoc committee of the American Society of Human Genetics concluded that, under current insurance practices, practicing geneticists will encounter difficulties being paid for genetic testing and genetic diagnosis. 18 
Genetic screening
Beyond genetic testing in individual cases are issues in routine screening of at-risk populations. Alcoholism may be one disease where screening could identify people who might benefit from counseling and other interventions, since chromosomes 1, 2, 7 and 11 may contain genes linked to alcoholism. However, broad-based screening of diseases that involve socially undesirable behaviors could 'medicalize' how society responds to social deviations. 19 False-positives and false-negatives both raise problems in carrier screening. To illustrate the latter, although a child of two cystic fibrosis (CF) carriers has a one in four chance of developing the disease, screening will fail to capture all of those affected, for there are 1000 mutations of the CF gene, although 70% of the alleles are single mutation (⌬F508).
An advantage of wider genetic testing and screening is that disease prevention plans could be tailored to individuals, much as prescription drug therapies are expected to become more personalized. However, this exciting prospect conveys additional concerns about cost and insurance coverage.
Prohibitions and questions of values
Like many health care frontiers, genetic services are susceptible to conflicts in cultural values. Among some cultures, a gender preference may exist, or a dominant family member may make decisions on behalf of the patient.
Enormous ethical dilemmas arise from the capability of gene enhancement and the potential creation of 'designer children'. As the accompanying cartoon illustrates, prospective parents may have the power to offend core social values.
Narrower issues arise from such technologies as the freezing of gametes. This process could be undertaken by youthful individuals who wish both to preserve their reproductive options and to minimize the chances of producing embryos with extra chromosomes or other abnormalities that become more frequent with parental age.
Although government might prohibit inheritable genetic modification (IGM) on ethical or moral grounds, like other proscriptions, this ban would be difficult to enforce. The American Association for the Advancement of Science has declared its opposition to IGM, and certain scientists oppose altering the germ-line, in order to protect future generations from disease. 20 Looming large over the genetic policy development world is the issue of whether, and under what circumstances, to permit human or animal cloning. Both are currently resisted by legislators. Over time, some allowances are likely. Regenerative medicine would allow an individual's malfunctioning cells to work properly. In addition, cloning could enhance predictive toxicology and the manufacture of human vaccines. Still, cloning on a large scale could become catastrophic, perpetuating copying errors that occur at conception and altering fundamental social relationships. Would a parent relate differently to his or her cloned offspring?
Supply policies
Another sphere of public policy action consists of funding to augment a supply of producers, providers or researchers. As an area holding great promise for the alleviation of human suffering, genetics could receive greater public sector funding during the next several years.
Potentially fertile areas for support, range from pharmacogenomics, intended to produce drugs that block disease, to comparative genomics, intended to plot evolutionary relationships within the animal kingdom. Support of bioinformatics could facilitate creation of tissue banks and other platforms for developing clinical products.
Gene Therapy
In addition, public support could focus on proteomics, since proteins, not genes, mediate disease and ultimately will be the targets of personalized prescribing. At least 100 000 proteins exist, each with 20 amino acids that can change over a person's lifetime.
Pharmaceutical products presumably will become more complicated, as diseases engender a multiplicity of disorders. Patients will consume complex drug cocktails with multiple interactions, each of which may need investigation. Great strides in clinical outcomes could result, because currently drugs work as intended only about one-third of the time. New, federally supported research funding schemes could be critical. Because tailored drugs benefit fewer people than most current drug products do, pharmaceutical manufacturers have little incentive to pursue their development.
One relatively simple scenario in the tailoring of drugs to fit a patient's genetic profile involves children with acute leukemia. A proportion of these children lack enough of the enzyme that breaks down a chemotherapeutic agent and prevents bone marrow damage. Here, as in the services sector, individual anecdotes could serve to promote government support.
With respect to funding research with clinical implications, gene therapy research may be heavily favored. Politicians and public health authorities will be attracted to the innovative nature of gene therapy. Also, gene therapy will be appealing as a strategy to prevent chronic disease and free patients from the burdens of lifelong drug regimens. In the wake of the 11 September 2001 terrorist attacks on the United States, the most persuasive justification for public funding of genetics-related product development would be to thwart biological or chemical warfare.
Approximately 90 medical genetics training programs exist in the United States. 21 Trainees may receive government support, but also are subject to regulation. To illustrate, licensure of genetic counselors is being undertaken at the state level, as with licensure of other health professions and occupations in the United States. Yet, training programs in health care often are funded by the US Department of Health and Human Services when federal policy-makers become convinced support is needed to avoid widespread personnel shortages.
Another area of supply policies revolves around patent law. From time to time, advocates of freer access to health care products market advocate relaxation of the stringent requirements of US patent law. Manufacturers of patented 'brand name' products contend that long-term patent protection makes research profitable. At this point there is nothing inherent in gene therapy products that would clearly justify an exception to patent law.
A model for predicting genetics policy
Government tilts in the direction of winds that track public attitudes. Public concerns now include protection of privacy and confidentiality of medical information, an interest in avoiding public or social insurance expenditures whose cost exceeds their benefits, and the human anecdotes whose emotional resonance is fanned by the mass media. In the United States, an even stronger wind in late 2001 is the commitment to defeat terrorists.
Of course, political winds often blow in contrary directions. Political leaders then may pursue compromise or whip up those winds for political gain or on grounds of principle.
Despite these countervailing forces, we make the following predictions: (1) Government will require an individual's specific and written consent for the disclosure of information about his or her own genotype. An exception might be made in cases where such a requirement would generate huge costs without significantly benefiting the described individuals. (2) Government will regulate databases containing information about individuals' genotypes probably through licensure, will restrict access to such information in the absence of individual consent, and will require controls to prevent hacking and to mask personal identifiers. (3) Courts will not be subject to broad restrictions on the use of individual genetic information. Courts and law enforcement agencies will be able to use such information in cases where a refusal to use such information would produce an unjust decision. (4) Driven by the power of the anecdote, governments will compel health insurers to pay for routine genetic screening and relatively low-cost genetic testing and counseling services. They will encourage more intensive genetic testing and counseling in cases where severe birth defects are likely. (5) The US Department of Health and Human Services will fund research on products useful in the prevention or personalized treatment of inherited diseases. A separate authorization may support genetics research into the control of bio-terrorism. (6) If a shortage of medical geneticists and genetic counselors persists, government will fund training programs. This is especially likely if a spectrum of individuals is harmed due to the unavailability of such personnel.
Conclusion
Within the democratic system, public policies are not strictly pre-determined. Public officials, opinion leaders and voters interact with events to produce policies. However, barring unlikely events the likely direction of public policy on genetics is relatively predictable.
So far, discussions about the social implications of genetic advances have emphasized ethical considerations. Ethics, as debated and promoted by intellectuals, affects the course of public policy, but does not control it. To affect public policy, experts on genetics must move beyond ethical issues into the domains of economics, health policy and politics.
